Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET
Company Participants
John Menditto – Vice President-Investor Relations and Corporate Communications
David Mazzo – President and Chief Executive Officer
Kristen Buck – Executive Vice President-Research and Development and Chief Medical Officer
James Nisco – Chief Accounting Officer
Conference Call Participants
Sara Nik – H.C. Wainwright
Will Hidell – Brookline Capital Markets
Pete Enderlin – MAZ Partners
Steve Brozak – WBB securities
Robert Sassoon – Water Tower Research
Robert LeBoyer – Noble Capital Markets
Operator
Welcome to the Lisata Therapeutics First Quarter 2024 Financial Results and Business Update Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions]. Please be advised that today’s conference is being recorded.
I’d now like to hand the conference over to our first speaker today John Menditto, Vice President of Investor Relations, and Corporate Communications. Please go ahead.
John Menditto
Thank you, operator, and good afternoon, everyone. Welcome to Lisata’s first quarter 2024 conference call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, President, and Chief Executive Officer; Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer; and James Nisco, Chief Accounting Officer.
Shortly before this call, we issued a press release announcing our first quarter 2024 financial results, which is available under the Investors and News section of the company website, along with the webcast replay of this call. If you have not received this news release or if you’d like to be added to the company’s email distribution list, please email me at jmenditto@lisata.com.
Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lisata. I encourage you to review the company’s filings with the Securities and Exchange Commission, including, without limitation, its Forms 10-Q, 8-K, and 10-K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, May 9, 2024. Lisata Therapeutics undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call.